30% of cancer drugs in the United States banned in Japan
Be used more than 30 percent of drugs against cancer in the United States is not authorized by the Japanese government has been and can not in patients in Japan, a group of doctors at the University of Kyoto must be administered . The University Translational Research Center (TRC) recently completed a study of drugs against cancer in the 2003 edition of the suite of current diagnosis and medical treatment has been completed, a manual widely used by doctors in the U.S. . According to the study must be approved 31 of the 101 drugs used against cancer in the United States or by the Health, Labour and Social Affairs Ministry.Of the 68 commonly used drugs in the U.S., the pain in cancer and mental health to alleviate poverty, have 27, not approved in Japan.The latest results
should cause the government to make a rapid improvement in the clinical trials process Ministre ineffective and approval of drugs. will be cancer drug approved in Japan as new drugs oxaliplatin, which is colorectal cancer, thalidomide, cancer of plasma cells in multiple myeloma and medicine gemtuzumab, a common treatment of leukemia to treat. They were all approved by the U.S. government as a standard cancer drugs. First-class medical treatment is not available because of the inertia in the medical system, delays in the approval process for cancer drugs and serious disadvantage was said, a professor of Kyoto UniversityMasanori Fukushima, a researcher at the Truth and Reconciliation Commission.Of cancer drugs, the government has approved about 80 not covered by insurance,
if administered off-label for cancer than those for which originally approved. On Tuesday, the Ministry conducted a study panel of the inaugural meeting of cancer drugs approved for wider use. The Ministry intends to expand the use of treatment from 10 to 15 drugs per year for other types of cancer. off-label problem, many specialists in the treatment of cancer, the meeting on Tuesday to extend the use of cancer drugs complained Pages: [1] 2